Loading
Every dated change on the records linked to Metastatic castration-resistant prostate cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
PSMA+ mCRPC after ARPI, before chemotherapy
rPFS significantly improved.
Median overall survival 24.
Median radiographic progression-free survival 8.
A milestone in how this cancer is treated.
HRR-mutant mCRPC with enzalutamide
rPFS HR 0.
rPFS HR 0.
Median imaging-based progression-free survival 11.
A milestone in how this cancer is treated.
mCRPC post-ARPI and taxane; pre-chemo 2025
PSMA+ mCRPC after ARPI and taxane
Overall survival not improved: stratified hazard ratio 1.
BRCA cohort rPFS HR 0.
rPFS HR 0.
A milestone in how this cancer is treated.
Closed early after 38 of a planned 148 men were randomised; AR-V7 prevalence 8 percent (95 percent confidence interval 6 to 10) among 953 prescreened men.
Median imaging-based progression-free survival 8.
Median symptomatic skeletal event-free survival 22.
Median overall survival 34.
Symptomatic bone-metastatic CRPC without visceral disease
OS HR 0.
Median radiographic progression-free survival 16.
Median overall survival 21.
Median overall survival 17.
A milestone in how this cancer is treated.
mCRPC pre-chemotherapy
mCRPC after docetaxel (pre-chemo 2014)
Median overall survival 18.
Median overall survival 22.
Median overall survival 24.
A milestone in how this cancer is treated.
mCRPC after docetaxel
Asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer
Median overall survival 25.
Median survival 15.
A milestone in how this cancer is treated.
Metastatic CRPC (with prednisone)
Median overall survival 17.
Median survival 18.
A milestone in how this cancer is treated.